Related news from
Mon, 15 Apr 2024 11:47:00 +0000	Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength? Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wed, 10 Apr 2024 10:00:00 +0000	Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM ET, featuring Horacio Kaufmann, MD, FAAN (Felicia B. Axelrod Professor of Neurology and Professor of Medicine at New York University Grossman School of Medicine) and Italo Biaggioni, MD (Professor of Medicine and Pharmacology Director, Vanderbilt Autonomic Dysfunction Center), who will discuss the unmet need and current treatment landscape
Wed, 03 Apr 2024 15:30:04 +0000	Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wed, 27 Mar 2024 15:30:21 +0000	Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report? Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tue, 12 Mar 2024 19:59:55 +0000	Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics The life of a bearish speculator can be dangerous and that’s part of the appeal of short-squeeze stocks: you can make life miserable for those attempting to cynically extract profits from others’ misery. At the most elemental level, I suppose it’s like watching a lion eating a safari hunter. Perhaps it’s a bit irrational but I believe I speak for most of us: we’d root for the lion and feel that the hunter received poetic justice. It’s what the kids call fool around and find out or FAFO. And that
Wed, 28 Feb 2024 15:35:57 +0000	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript February 26, 2024 Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.04. TBPH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, good afternoon. I’d […]
Tue, 27 Feb 2024 16:47:00 +0000	Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time. Stock rises.
Mon, 26 Feb 2024 22:25:03 +0000	Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates Theravance Bio (TBPH) delivered earnings and revenue surprises of 175% and 0.43%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Mon, 26 Feb 2024 21:05:00 +0000	Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the fourth quarter of 2023 and full-year ended December 31, 2023.
Thu, 22 Feb 2024 11:00:00 +0000	Theravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the CNS Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference in Boston, MA on Tuesday, March 5 at 10:30 am ET (7:30 am PT/3:30 pm GMT). Members of Theravance Biopharma senior management will be hosting one on one meetings at the conference.
Thu, 15 Feb 2024 12:07:35 +0000	Will Theravance Biopharma (NASDAQ:TBPH) Spend Its Cash Wisely? We can readily understand why investors are attracted to unprofitable companies. For example, although...
Wed, 14 Feb 2024 11:00:00 +0000	Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2023 financial results and provide a business update after market close on Monday, February 26, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day.
Fri, 19 Jan 2024 10:59:43 +0000	Analysts Expect Breakeven For Theravance Biopharma, Inc. (NASDAQ:TBPH) Before Long Theravance Biopharma, Inc. ( NASDAQ:TBPH ) is possibly approaching a major achievement in its business, so we would...
Fri, 12 Jan 2024 14:35:06 +0000	Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Fri, 05 Jan 2024 11:00:00 +0000	Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of COPD.
Sun, 24 Dec 2023 18:08:45 +0000	7 Short-Squeeze Stocks That Are Screaming for Speculation While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it’s time to address this speculative practice under a three-dimensional lens. First, market gamblers shouldn’t just focus on short interest as a percentage of float. Don’t get me wrong. Whenever short interest hits 10% or close to it, that’s an elevated reading. And when this metric runs above 20%, we’re talking about a security that ha
Thu, 21 Dec 2023 22:00:00 +0000	Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020.
Mon, 18 Dec 2023 11:00:00 +0000	Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team including Rick E Winningham, CEO, and Aziz Sawaf, CFO, will hold investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, in San Francisco, CA.
Sat, 09 Dec 2023 13:35:10 +0000	The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable Generally speaking long term investing is the way to go. But no-one is immune from buying too high. Zooming in on an...
Thu, 07 Dec 2023 16:30:57 +0000	Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue? Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.